These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 32247073

  • 21. Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.
    Chihara A, Tanaka A, Morimoto T, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Ueda S, Node K.
    Cardiovasc Diabetol; 2019 Nov 16; 18(1):158. PubMed ID: 31733647
    [Abstract] [Full Text] [Related]

  • 22. Short article: A randomized-controlled study of sitagliptin for treating diabetes mellitus complicated by nonalcoholic fatty liver disease.
    Deng XL, Ma R, Zhu HX, Zhu J.
    Eur J Gastroenterol Hepatol; 2017 Mar 16; 29(3):297-301. PubMed ID: 27832040
    [Abstract] [Full Text] [Related]

  • 23. Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.
    Murai K, Katsuno T, Miyagawa J, Matsuo T, Ochi F, Tokuda M, Kusunoki Y, Miuchi M, Namba M.
    Drugs R D; 2014 Dec 16; 14(4):301-8. PubMed ID: 25420579
    [Abstract] [Full Text] [Related]

  • 24. Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.
    Widlansky ME, Puppala VK, Suboc TM, Malik M, Branum A, Signorelli K, Wang J, Ying R, Tanner MJ, Tyagi S.
    Vasc Med; 2017 Jun 16; 22(3):189-196. PubMed ID: 28145158
    [Abstract] [Full Text] [Related]

  • 25. Sitagliptin on carotid intima-media thickness in type 2 diabetes patients receiving primary or secondary prevention of cardiovascular disease: A subgroup analysis of the PROLOGUE study.
    Tanaka A, Yoshida H, Nanasato M, Oyama JI, Ishizu T, Ajioka M, Ishiki R, Saito M, Shibata Y, Kaku K, Maemura K, Higashi Y, Inoue T, Murohara T, Node K.
    Int J Cardiol; 2018 Nov 15; 271():331-335. PubMed ID: 29803341
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
    Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S.
    Cardiovasc Diabetol; 2020 Jun 15; 19(1):89. PubMed ID: 32539832
    [Abstract] [Full Text] [Related]

  • 30. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
    Nauck MA, McGuire DK, Pieper KS, Lokhnygina Y, Strandberg TE, Riefflin A, Delibasi T, Peterson ED, White HD, Scott R, Holman RR.
    Cardiovasc Diabetol; 2019 Sep 03; 18(1):116. PubMed ID: 31481069
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus--a randomized controlled trial START-J study.
    Hibuse T, Maeda N, Kishida K, Kimura T, Minami T, Takeshita E, Hirata A, Nakagawa Y, Kashine S, Oka A, Hayashi M, Nishizawa H, Funahashi T, Shimomura I.
    Cardiovasc Diabetol; 2014 May 24; 13():96. PubMed ID: 24884787
    [Abstract] [Full Text] [Related]

  • 35. Short and Long Term Effects of a DPP-4 Inhibitor Versus Bedtime NPH Insulin as ADD-ON Therapy in Patients with Type 2 Diabetes.
    da Silva GM, Nogueira KC, Fukui RT, Correia MR, Dos Santos RF, da Silva ME.
    Curr Pharm Des; 2016 May 24; 22(44):6716-6721. PubMed ID: 27928958
    [Abstract] [Full Text] [Related]

  • 36. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
    Peng XV, Marcinak JF, Raanan MG, Cao C.
    Diabetes Obes Metab; 2017 Aug 24; 19(8):1127-1134. PubMed ID: 28239939
    [Abstract] [Full Text] [Related]

  • 37. Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD.
    Muanda FT, Weir MA, Bathini L, Clemens KK, Perkovic V, Sood MM, McArthur E, Sontrop JM, Kim RB, Garg AX.
    Clin J Am Soc Nephrol; 2020 Dec 07; 15(12):1728-1739. PubMed ID: 33239410
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
    Raschi E, Poluzzi E, Koci A, Antonazzo IC, Marchesini G, De Ponti F.
    Nutr Metab Cardiovasc Dis; 2016 May 07; 26(5):380-6. PubMed ID: 27067162
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.